New Promising Addition to our SWI QuickPicks
Six Analysts Price Target of $14.33
Los Angeles, March 16, 2017 - Today SWI announces a very promising addition, Adaptimmune, Inc.,(ADAP:NasdaqGS) to its biotech "QuickPicks Portfolio", a portfolio that has consistently outperformed all leading major indices. The Quicks top performers are frequently acquired for our SWI Portfolio.


Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary SPEAR T-cell platform. Its platform enables to identify cancer targets; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients. The company’s lead program includes NY-ESO-1 and LAGE-1a cancer antigens, which are in Phase I/II clinical trials for patients with solid tumors, as well as hematological cancer types, including synovial sarcoma, multiple myeloma, non-small cell lung cancer (NSCLC), and ovarian cancer; and pilot trial for myxoid round cell liposarcoma

  • Completed March 2017 public offering and April 2017 registered direct offering to Matrix Capital Management Company, LP (“Matrix”), raising total net proceeds of $103.2 million; 
  • Initiated AFP SPEAR T-cell therapy study in hepatocellular carcinoma;
  • Announced FDA acceptance of IND application for SPEAR T-cell therapy targeting MAGE-A4 in multiple solid tumors;
  • Announced nomination by GlaxoSmithKline of second target, PRAME, under strategic multi-target collaboration;
  • Fully enrolled Cohort 4 of a pilot study of NY-ESO SPEAR T-cells in synovial sarcoma, and expanded this cohort to include an additional five patients; a data update on all cohorts in this study will be presented in an oral presentation at the upcoming ASCO annual meeting in June;
  • Received FDA notification of permission to proceed with new cell manufacturing process for NY‑ESO phase I/II studies, and this process is being used for clinical manufacture; and
  • Announced that Dr. Helen Tayton-Martin had assumed new role of Chief Business Officer, and that William Bertrand had joined Adaptimmune as Chief Operating Officer

ADAP is trading at $5.13 at the close of market yesterday
The Six Analysts Price Target is $14.33

If you want to follow all other companies that we cover with more in depth research reports, go to our research site at to download the reports,
or visit for up to date news on the covered companies.
Please feel free to
re-distribute the reports to your friends and colleagues.
Rainer Poertner - Chief Analyst
S tockWatchIndex  and SWI Research (SWI) are not registered investment advisers and the information  provided herein or any other SWI publication is not to be construed as personal financial advice, or a solicitation to buy or sell stock. SWI makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in its publications or on its web sites. Some of the published information has been provided by the companies covered, generated by publicly available sources, or what SWI deems to be reliable third party entities, but SWI does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or  warrant any results from use of the information. Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein. StockWatchIndex is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in this publication, any other SWI publication, or its web sites and is not obligated to update and/or correct information. No liability is accepted by StockWatchIndex whatsoever for any direct, indirect or consequential loss arising from the use of the information. SWI expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided.  SWI has not been compensated for this report, but may hold or plan to acquire positions of every stock in this report for its portfolio a nd reserves the right to buy or sell positions at its sole  discretion. The included information is subject to change without notice. Please visit!legal-ease/lmvw1   for a full text of our Disclaimer, Privacy policy and Terms of Use.